The CEO is incredibly capable. He may not be a genius at ASX listing stuff. BUT in regards to the business he is very knowledgeable and capable of growing this business long term.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%